Rapid Decline of Mpox Antibody Responses Following MVA-BN Vaccination
Collier, A.-r.; McMahan, K.; Jacob-Dolan, C.; Liu, J.; Borducchi, E.; Moss, B.; Barouch, D. H.
Show abstract
The replication-incompetent modified vaccinia Ankara-Bavarian Nordic vaccine (MVA-BN; Jynneos) was deployed during the 2022 clade IIb mpox outbreak. On August 14, 2024, the World Health Organization declared the mpox clade Ib outbreak in the Democratic Republic of the Congo a public health emergency of international concern, which has raised the question about the durability of vaccine immunity after MVA-BN vaccination. In this study, we show that the MVA-BN vaccine generated mpox serum antibody responses that largely waned after 6-12 months.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: A Randomised, Comparator-Controlled, Phase 2 Trial 95%
- Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting 95%
- Cellular and Humoral Immunity to Ebola Zaire Glycoprotein and Viral Vector Proteins Following Immunization with Recombinant Vesicular Stomatitis Virus-Based Ebola Vaccine (rVSVΔG-EBOV-GP) 95%
Similar papers in this journal
- Heterologous SARS-CoV-2 Booster Vaccinations – Preliminary Report 95%
- Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar 94%
- Effectiveness of the BNT162b2 vaccine against SARS-CoV-2 infection among children and adolescents in Qatar 94%
Similar papers in this journal
- A Phase 1: Safety and Immunogenicity Trial of an Inactivated SARS-CoV-2 Vaccine-BBV152 95%
- Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report 94%
- Immunogenicity and Safety Following a Homologous Booster Dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): A Phase 2 Randomized Placebo-Controlled Trial 94%
Similar papers in this journal
- Extended interval BNT162b2 vaccination enhances peak antibody generation in older people 94%
- Immunogenicity, safety and efficacy of sequential immunizations with an SIV-based IDLV expressing CH505 Envs 94%
- Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19 disease in hamsters 92%
Similar papers in this journal
- Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial 96%
- Homologous and Variant-Specific Memory B-Cell and Antibody Responses after SARS-CoV-2 mRNA Vaccination 93%
- Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.